Literature DB >> 9226696

Influence of parasite presence on the immunologic profile of peripheral blood mononuclear cells from chagasic patients after specific drug therapy.

W O Dutra1, Z M da Luz, J R Cançado, M E Pereira, R M Brigido-Nunes, L M Galvão, D G Colley, Z Brener, G Gazzinelli, J F Carvalho-Parra.   

Abstract

The aim of this study is to evaluate the effects of parasite clearance on the immunological profile of peripheral blood mononuclear cells (PBMC) from chagasic patients submitted to specific drug therapy. PBMC were examined by flow cytometry and proliferative responsiveness to Trypanosoma cruzi-related stimuli. Three groups of patients were studied: not treated (NT), treated not cured (TNC) and cured (C). All data were compared to values from uninfected individuals (NI). NT displayed a lower percentage of CD3+ cells as compared to NI, while TNC and C had mean values that were between those from NI and NT. Infected patients had double the percent of CD3+ HLA-DR+ cells, independent of the efficacy of the treatment. Thus, absence of circulating parasites did not reduce T cell activation in Chagas' disease. NT displayed a higher percentage of CD5+ B cells as compared to NI, while TNC and C had mean values between those from NI and NT. In contrast to the phenotypic data, the in vitro mean proliferative responses to parasite-related stimuli of PBMC from C were reduced to the low mean levels observed in NI. These striking differences were statistically different from the high responses seen in NT and TNC. Our data suggest that proliferative responses of PBMC from C reflect immunological changes due elimination of parasite. However, successful treatment did not alter the levels of peripheral T cell activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9226696     DOI: 10.1046/j.1365-3024.1996.d01-29.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  12 in total

1.  Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease.

Authors:  S A Laucella; E L Segura; A Riarte; E S Sosa
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity?

Authors:  D M Vitelli-Avelar; R Sathler-Avelar; R L Massara; J D Borges; P S Lage; M Lana; A Teixeira-Carvalho; J C P Dias; S M Elói-Santos; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.

Authors:  Bianca Perdigão Olivieri; Vinícius Cotta-De-Almeida; Tania Araújo-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.

Authors:  Paulo Marcos da Matta Guedes; Julio A Urbina; Marta de Lana; Luis C C Afonso; Vanja M Veloso; Washington L Tafuri; George L L Machado-Coelho; Egler Chiari; Maria Terezinha Bahia
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Glycoinositolphospholipids from Trypanosoma cruzi induce B cell hyper-responsiveness in vivo.

Authors:  A M Bilate; J O Previato; L Mendonça-Previato; L M Peçanha
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

6.  Trypanosoma cruzi-induced activation of functionally distinct αβ and γδ CD4- CD8- T cells in individuals with polar forms of Chagas' disease.

Authors:  Fernanda Nobre Amaral Villani; Manoel Otávio da Costa Rocha; Maria do Carmo Pereira Nunes; Lis Ribeiro do Valle Antonelli; Luisa Mourão Dias Magalhães; Janete Soares Coelho dos Santos; Kenneth J Gollob; Walderez O Dutra
Journal:  Infect Immun       Date:  2010-08-09       Impact factor: 3.441

Review 7.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease.

Authors:  Fabiana S Machado; Walderez O Dutra; Lisia Esper; Kenneth J Gollob; Mauro M Teixeira; Stephen M Factor; Louis M Weiss; Fnu Nagajyothi; Herbert B Tanowitz; Nisha J Garg
Journal:  Semin Immunopathol       Date:  2012-10-18       Impact factor: 9.623

8.  Pathogenesis of Chagas disease: time to move on.

Authors:  Fabiana S Machado; Kevin M Tyler; Fatima Brant; Lisia Esper; Mauro M Teixeira; Herbert B Tanowitz
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

9.  Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with Trypanosoma cruzi antigens.

Authors:  Renato Sathler-Avelar; Danielle Marquete Vitelli-Avelar; Silvana Maria Elói-Santos; Eliane Dias Gontijo; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  BMC Infect Dis       Date:  2012-05-24       Impact factor: 3.090

10.  Changes in Proteome Profile of Peripheral Blood Mononuclear Cells in Chronic Chagas Disease.

Authors:  Nisha Jain Garg; Kizhake V Soman; Maria P Zago; Sue-Jie Koo; Heidi Spratt; Susan Stafford; Zinzi N Blell; Shivali Gupta; Julio Nuñez Burgos; Natalia Barrientos; Allan R Brasier; John E Wiktorowicz
Journal:  PLoS Negl Trop Dis       Date:  2016-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.